Germany’s EVANIUM Raises €2.2M To Boost Nutraceutical Ingredient Absorption

The round was backed by FoodLabs and Feast Ventures, along with participation from existing angel investors.

The company will use the funds to scale its OPTISOLV® technology, grow its team, advance clinical studies and strengthen commercial partnerships across nutraceuticals, nutricosmetics and functional food sectors.

Founded in 2019 by Felix Rolka, David Ofner, and Carlo Werkmann, EVANIUM develops technologies to improve the solubility, stability, and bioavailability of ingredients used in nutraceuticals, functional foods, nutricosmetics, and pharmaceuticals.

Read Also - Peak Quantum Raises €2.2M In Pre-seed Funding For Quantum Chip Development

At the core of its approach is the proprietary OPTISOLV® technology platform which enhances ingredient absorption and effectiveness enabling partners to create high-performance, clean-label products.

The company highlights a key challenge in the nutraceutical industry: despite high prices, many supplements deliver limited benefits because active ingredients are poorly absorbed by the body sometimes at rates below 1%.

EVANIUM addresses this inefficiency with bioavailability-enhanced ingredients built on a dual-layer coating system. OPTISOLV® combines a cyclodextrin-based inner core with an outer phospholipid shell, keeping natural actives stable in a crystal-free, highly dispersible form.

This structure helps prevent re-agglomeration, improves permeability, and significantly increases solubility and absorption using only natural materials.

For difficult compounds such as curcumin, the company reports improvements of over 1,000x in solubility and more than 170x in digestive release compared to the native form, outperforming traditional phospholipid-based solutions in comparative tests.

In 2025 EVANIUM launched OPTISOLV® Curcumin in partnership with Hevert-Arzneimittel, a leading German herbal medicine company. This marked the company’s first commercial rollout in Germany and demonstrated that OPTISOLV® is a market-ready technology for established B2B applications.

The company has also filed its fourth patent, reinforcing OPTISOLV as the core of a scalable ingredient platform. Its product portfolio now includes four functional ingredients Curcumin, Berberine, Boswellia, and Passiflora. EVANIUM is also preparing additional clinical studies to further validate its formulations.

Following its seed funding round, the company has expanded to more than 12 employees. In 2026, it has already manufactured and delivered over two tons of material.

“EVANIUM addresses one of the most expensive inefficiencies in the nutraceutical industry. Improving bioavailability doesn’t just benefit brands, it directly improves consumer outcomes,” said Adrian Friederich, Head of Investments at FoodLabs.

“The future of nutraceuticals lies not in higher dosages but in smarter formulations. OPTISOLV turns promising bioactives into high‑performance ingredients, enabling truly effective products. With this funding we are able to accelerate the scale of our impact ” said Felix Rolka co‑founder and CEO of EVANIUM.